Formulation and optimization of chitosan-based amorphous fenbendazole microparticles through a design of experiment approach. (2024)

Peer-Reviewed Study · Lina Vargas Michelena; Giselle R Bedogni; Miguel O Jara et al. · December 25, 2024

Lina Vargas Michelena et al., 2024-12-25: Pharmaceutical development paper on chitosan-crosslinked amorphous fenbendazole microparticles, aimed at the drug's very low aqueous solubility.

It is a lipophilic benzimidazole derivative with low water solubility (<0.1 g/L) recently studied for repositioning in cancer treatment.

Lina Vargas Michelena et al., 2024-12-25: Pharmaceutical development paper on chitosan-crosslinked amorphous fenbendazole microparticles, aimed at the drug's very low aqueous solubility. Study type: formulation and in vitro dissolution. N: not applicable. Country: Argentina and USA (University of Buenos Aires; University of Texas at Austin). Dose: not applicable; solubility quoted as below 0.1 g/L. Funder: not stated in the record. Declared conflicts: 'The authors declare that they have no known competing financial interests…'. Comparator: non-encapsulated drug. Study type: lab.